2 weeks Ago By Defense World Staff
Renaissance Technologies LLC increased its holdings in Assertio Holdings, Inc. ( NASDAQ:ASRT – Free Report ) by 13.7% in the second quarter, according to its most recent filing with the Securities and Exchange Commission.
The firm owned 2,377,614 shares of the company’s stock after purchasing an additional 285,655 shares during the quarter. Renaissance Technologies LLC owned 2.50% of Assertio worth $2,948,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the business. Perritt Capital Management Inc raised its holdings in Assertio by 16.1% in the 2nd quarter.
Perritt Capital Management Inc now owns 426,850 shares of the company’s stock worth $529,000 after purchasing an additional 59,333 shares during the period. Los Angeles Capital Management LLC purchased a new position in shares of Assertio during the second quarter worth $77,000. SummerHaven Investment Management LLC boosted its position in shares of Assertio by 10.
9% during the second quarter. SummerHaven Investment Management LLC now owns 161,171 shares of the company’s stock worth $200,000 after buying an additional 15,779 shares during the period. Vanguard Group Inc.
boosted its holdings in Assertio by 0.8% in the first quarter. Vanguard Group Inc.
now owns 4,919,614 shares of the company’s stock valued at $4,719,000 after purchasing an additional 41,071 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in Assertio by 22,096.
2% in the first quarter. Russell Investments Group Ltd. now owns 2,347,024 shares of the company’s stock valued at $2,251,000 after purchasing an additional 2,336,450 shares during the period.
Institutional investors and hedge funds own 48.96% of the company’s stock. Assertio Stock Performance NASDAQ ASRT opened at $1.
18 on Tuesday. Assertio Holdings, Inc. has a 52-week low of $0.
73 and a 52-week high of $2.60. The business’s 50-day moving average price is $1.
26 and its 200 day moving average price is $1.15. The firm has a market cap of $112.
25 million, a P/E ratio of -0.29 and a beta of 0.79.
The company has a quick ratio of 1.51, a current ratio of 1.93 and a debt-to-equity ratio of 0.
29. Wall Street Analyst Weigh In A number of research analysts recently issued reports on the company. HC Wainwright initiated coverage on Assertio in a report on Wednesday, July 3rd.
They issued a “buy” rating and a $4.00 target price for the company. Maxim Group started coverage on Assertio in a research report on Friday, July 26th.
They set a “buy” rating and a $3.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock.
According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $3.44. Check Out Our Latest Research Report on ASRT Assertio Company Profile ( Free Report ) Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States.
Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. Recommended Stories Five stocks we like better than Assertio Natural Gas Prices Continue To Rally, These Stocks Should Benefit TJX Stock: A Buying Opportunity Before the Holiday Rush Investing in the High PE Growth Stocks Micron’s Blowout Results Pave the Way for Seagate’s Stock Surge How to Invest in Tech Stocks and Top Tech Stocks to Consider Zeta Global’s AI Cloud: Your Secret Weapon for Massive Growth Receive News & Ratings for Assertio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assertio and related companies with MarketBeat.com's FREE daily email newsletter .
.
